Shanghai Pharm Valley

Shanghai PharmValley (Shanghai PharmValley Corp.) is a biotechnology company and research organization headquartered in the Zhangjiang Hi-Tech Park of Shanghai, China. Founded by Michael Xin Hui, the founder of the major CRO ShangPharma, the company operates as a strategic hub for life science innovation, providing laboratory infrastructure, incubation services, and technical support to the biopharmaceutical industry. Through its Shanghai PharmValley Innovation Institute of Biomedicine, the company focuses on the modernization of Traditional Chinese Medicine (TCM) and the development of novel therapeutics derived from natural products. Its R&D pipeline features programs such as Ginsenoside Rh2 for oncology and Puruixiao Capsule for the treatment of prostatitis, alongside research into advanced molecular degraders targeting HMG-CoA reductase for cardiovascular health. The company plays a dual role as both a drug developer and a key service provider within the Shanghai "Pharma Valley" ecosystem.